Skip Navigation


ToxSci Advance Access originally published online on May 9, 2006
Toxicological Sciences 2006 92(2):368-377; doi:10.1093/toxsci/kfl002
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
92/2/368    most recent
kfl002v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Xiao, S.
Right arrow Articles by Corton, J. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Xiao, S.
Right arrow Articles by Corton, J. C.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2006. Published by Oxford University Press on behalf of the Society of Toxicology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Activation of Peroxisome Proliferator–Activated Receptor Alpha Enhances Apoptosis in the Mouse Liver

Shen Xiao*,1, Steven P. Anderson{dagger},2, Cynthia Swanson*, Rainer Bahnemann{ddagger}, Kenneth A. Voss§, Anja J. Stauber*,3 and J. Christopher Corton*,4

* CIIT Centers for Health Research, Research Triangle Park, North Carolina 27709; {dagger} Investigative Toxicology and Pathology Group, Safety Assessment, GlaxoSmithKline Research & Development, Research Triangle Park, North Carolina 27709-3998; {ddagger} Department of Toxicology, BASF Aktiengesellschaft, Ludwigshafen, Germany; and § USDA, Athens, Georgia 30604-5677

Received December 18, 2005; accepted April 13, 2006

Chronic exposure to peroxisome proliferators (PPs) leads to increased incidence of liver tumors in rodents. Liver tumor induction is thought to require increased hepatocyte proliferation and suppression of apoptosis. Transcript profiling showed increased expression of proapoptotic genes and decreased expression of antiapoptotic genes in the livers of mice exposed to the PP WY-14,643 (WY). We tested the hypothesis that prior exposure to WY would increase susceptibility to apoptosis inducers such as Jo2, an antibody which activates the Fas (Apo-1/CD95) death pathway. When compared to their untreated counterparts, wild-type mice pretreated with WY exhibited increased caspase-3 activation and hepatocyte apoptosis following challenge with Jo2. Livers from WY-treated peroxisome proliferator–activated receptor alpha (PPAR{alpha})-null mice were resistant to the effects of Jo2. In the absence of Jo2 and detectable apoptosis, wild-type mice treated with WY exhibited increases in the activated form of caspase-9. As caspase-9 is a component of the apoptosome, we examined the expression of upstream effectors of apoptosome activity including members of the Bcl-2 family. The levels of the antiapoptotic Mcl-1 transcript and protein were significantly decreased by PPs. PPAR{alpha}-null mice were also resistant to another treatment (concanavalin A) that induces hepatocyte apoptosis. These results (1) indicate that PPAR{alpha} activation increases sensitivity of the liver to apoptosis and (2) identify a mechanism by which PPAR{alpha} could serve as a pharmacological target in diseases where apoptosis is a contributing feature.

Key Words: peroxisome proliferators; liver tumor; hepatocyte proliferation; apoptosis; caspase.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.